Ann Janssens Selected Research

romiplostim

1/2021	Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.
1/2020	Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
2/2017	A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
6/2016	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
2/2015	Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
1/2015	Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
7/2012	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
4/2012	Romiplostim for the treatment of primary immune thrombocytopenia.
9/2011	Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ann Janssens Research Topics

Disease

20	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 09/2005
13	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2021 - 08/2008
7	Hemorrhage 01/2022 - 07/2012
7	Neoplasms (Cancer) 01/2021 - 11/2004
4	Lymphoma (Lymphomas) 03/2022 - 11/2004
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 10/2017
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 06/2017
4	Neutropenia 01/2020 - 05/2015
3	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 03/2022 - 04/2018
3	Disease Progression 12/2020 - 02/2007
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2018 - 12/2008
3	Fatigue 01/2018 - 12/2015
3	Thrombocytopenia (Thrombopenia) 06/2016 - 04/2012
2	COVID-19 12/2021 - 01/2020
2	Multiple Sclerosis 03/2018 - 01/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2009 - 09/2006
1	Residual Neoplasm 01/2022
1	Sudden Infant Death (SID) 02/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 02/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2021
1	Infections 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Relapsing-Remitting Multiple Sclerosis 03/2018
1	Cough 12/2015
1	Diarrhea 12/2015
1	Vomiting 12/2015
1	Anemia 12/2015
1	Nausea 12/2015
1	Prolymphocytic Leukemia 05/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2015
1	Encephalitis (Encephalitis, Rasmussen) 05/2014
1	Hyperuricemia 03/2013
1	Toxoplasmosis 04/2010
1	Breakthrough Infections 04/2010
1	Opportunistic Infections (Opportunistic Infection) 04/2010
1	Hematologic Neoplasms (Hematological Malignancy) 12/2009

Drug/Important Bio-Agent (IBA)

10	Inosine Triphosphate (ITP)IBA 01/2021 - 08/2008
9	romiplostim FDA Link 01/2021 - 09/2011
8	Rituximab (Mabthera)FDA Link 03/2022 - 11/2004
7	ibrutinibIBA 01/2022 - 12/2015
5	Chlorambucil (Leukeran)FDA Link 01/2022 - 05/2015
5	Bendamustine Hydrochloride FDA Link 12/2020 - 01/2016
4	obinutuzumabIBA 03/2022 - 05/2014
4	fludarabineIBA 05/2015 - 08/2006
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2006
3	Alemtuzumab (Campath)FDA Link 03/2018 - 09/2006
3	ofatumumab FDA Link 09/2016 - 05/2015
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 02/2016
2	venetoclaxIBA 01/2022 - 01/2021
2	acalabrutinibIBA 01/2022 - 01/2020
2	Oxygen (Dioxygen)IBA 12/2021 - 01/2020
2	Peptides (Polypeptides)IBA 01/2021 - 01/2015
2	Monoclonal AntibodiesIBA 01/2021 - 03/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2011 - 08/2008
1	GalliumIBA 03/2022
1	CreatinineIBA 01/2022
1	Intravenous Immunoglobulins (IVIG)FDA Link 02/2021
1	Ru265IBA 01/2021
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2021
1	FluorineIBA 01/2021
1	NivolumabIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021
1	Warfarin (Coumadin)FDA LinkGeneric 01/2020
1	Vitamin K FDA Link 01/2020
1	ChemokinesIBA 10/2019
1	Inositol 1,4,5-Trisphosphate Receptors (Inositol Triphosphate Receptor)IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Inositol 1,4,5-TrisphosphateIBA 01/2019
1	XL765IBA 04/2018
1	blinatumomabIBA 10/2017
1	Cyclin D1IBA 06/2017
1	alvocidib (flavopiridol)IBA 05/2015
1	ethyl 2- amino- 6- bromo- 4- (1- cyano- 2- ethoxy- 2- oxoethyl)- 4H- chromene- 3- carboxylateIBA 01/2015
1	Collagen Type I (Type I Collagen)IBA 01/2015
1	Allopurinol (Remid)FDA LinkGeneric 03/2013
1	acadesineIBA 03/2013
1	rozrolimupabIBA 11/2012
1	AntibodiesIBA 11/2012
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 04/2010
1	Antineoplastic Agents (Antineoplastics)IBA 12/2009
1	SteroidsIBA 10/2009
1	GlucocorticoidsIBA 10/2009
1	CyclinsIBA 12/2008
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 02/2007
1	Messenger RNA (mRNA)IBA 02/2007
1	Pharmaceutical PreparationsIBA 08/2006
1	Vincristine (Oncovin)FDA LinkGeneric 08/2006
1	Colchicine FDA LinkGeneric 08/2006
1	Cisplatin (Platino)FDA LinkGeneric 08/2006
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2006

Therapy/Procedure

7	Therapeutics 01/2021 - 11/2004
4	Drug Therapy (Chemotherapy) 03/2022 - 08/2006
2	Self Administration (Administration, Self) 01/2020 - 02/2015
2	Radiotherapy 08/2006 - 11/2004
2	Radioimmunotherapy 08/2006 - 11/2004
1	Critical Care (Surgical Intensive Care) 01/2020
1	Renal Dialysis (Hemodialysis) 05/2015
1	Hematopoietic Stem Cell Transplantation 04/2010
1	Transplantation 12/2009
1	Aftercare (After-Treatment) 08/2006